Huntington's disease: Effect of cysteamine, a somatostatin-depleting agent

C. Shults, L. Steardo, P. Barone, E. Mohr, J. Juncos, C. Serrati, P. Fedio, C. A. Tamminga, T. N. Chase

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Somatostatin levels in the basal ganglia are elevated in Huntington's disease. A controlled therapeutic trial of the somatostatin-depleting agent, cysteamine, was therefore conducted in five patients, including one with the rigid-akinetic form. Maximum tolerated dosage for 2 weeks produced no consistent change in extrapyramidal or dementia scores. Somatostatin concentrations were not significantly altered in plasma or CSF. Growth hormone levels, on the other hand, more than doubled, suggesting a functionally significant decrease in central somatostatin levels.

Original languageEnglish (US)
Pages (from-to)1099-1102
Number of pages4
JournalNeurology
Volume36
Issue number8
StatePublished - 1986

Fingerprint

Cysteamine
Huntington Disease
Somatostatin
Basal Ganglia
Growth Hormone
Dementia
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Shults, C., Steardo, L., Barone, P., Mohr, E., Juncos, J., Serrati, C., ... Chase, T. N. (1986). Huntington's disease: Effect of cysteamine, a somatostatin-depleting agent. Neurology, 36(8), 1099-1102.

Huntington's disease : Effect of cysteamine, a somatostatin-depleting agent. / Shults, C.; Steardo, L.; Barone, P.; Mohr, E.; Juncos, J.; Serrati, C.; Fedio, P.; Tamminga, C. A.; Chase, T. N.

In: Neurology, Vol. 36, No. 8, 1986, p. 1099-1102.

Research output: Contribution to journalArticle

Shults, C, Steardo, L, Barone, P, Mohr, E, Juncos, J, Serrati, C, Fedio, P, Tamminga, CA & Chase, TN 1986, 'Huntington's disease: Effect of cysteamine, a somatostatin-depleting agent', Neurology, vol. 36, no. 8, pp. 1099-1102.
Shults C, Steardo L, Barone P, Mohr E, Juncos J, Serrati C et al. Huntington's disease: Effect of cysteamine, a somatostatin-depleting agent. Neurology. 1986;36(8):1099-1102.
Shults, C. ; Steardo, L. ; Barone, P. ; Mohr, E. ; Juncos, J. ; Serrati, C. ; Fedio, P. ; Tamminga, C. A. ; Chase, T. N. / Huntington's disease : Effect of cysteamine, a somatostatin-depleting agent. In: Neurology. 1986 ; Vol. 36, No. 8. pp. 1099-1102.
@article{0a0ad087f18a49c39e80a776c6dd8fb4,
title = "Huntington's disease: Effect of cysteamine, a somatostatin-depleting agent",
abstract = "Somatostatin levels in the basal ganglia are elevated in Huntington's disease. A controlled therapeutic trial of the somatostatin-depleting agent, cysteamine, was therefore conducted in five patients, including one with the rigid-akinetic form. Maximum tolerated dosage for 2 weeks produced no consistent change in extrapyramidal or dementia scores. Somatostatin concentrations were not significantly altered in plasma or CSF. Growth hormone levels, on the other hand, more than doubled, suggesting a functionally significant decrease in central somatostatin levels.",
author = "C. Shults and L. Steardo and P. Barone and E. Mohr and J. Juncos and C. Serrati and P. Fedio and Tamminga, {C. A.} and Chase, {T. N.}",
year = "1986",
language = "English (US)",
volume = "36",
pages = "1099--1102",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Huntington's disease

T2 - Effect of cysteamine, a somatostatin-depleting agent

AU - Shults, C.

AU - Steardo, L.

AU - Barone, P.

AU - Mohr, E.

AU - Juncos, J.

AU - Serrati, C.

AU - Fedio, P.

AU - Tamminga, C. A.

AU - Chase, T. N.

PY - 1986

Y1 - 1986

N2 - Somatostatin levels in the basal ganglia are elevated in Huntington's disease. A controlled therapeutic trial of the somatostatin-depleting agent, cysteamine, was therefore conducted in five patients, including one with the rigid-akinetic form. Maximum tolerated dosage for 2 weeks produced no consistent change in extrapyramidal or dementia scores. Somatostatin concentrations were not significantly altered in plasma or CSF. Growth hormone levels, on the other hand, more than doubled, suggesting a functionally significant decrease in central somatostatin levels.

AB - Somatostatin levels in the basal ganglia are elevated in Huntington's disease. A controlled therapeutic trial of the somatostatin-depleting agent, cysteamine, was therefore conducted in five patients, including one with the rigid-akinetic form. Maximum tolerated dosage for 2 weeks produced no consistent change in extrapyramidal or dementia scores. Somatostatin concentrations were not significantly altered in plasma or CSF. Growth hormone levels, on the other hand, more than doubled, suggesting a functionally significant decrease in central somatostatin levels.

UR - http://www.scopus.com/inward/record.url?scp=0022536654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022536654&partnerID=8YFLogxK

M3 - Article

C2 - 2874527

AN - SCOPUS:0022536654

VL - 36

SP - 1099

EP - 1102

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -